In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...

The High Court ruled on a significant patent dispute involving Pfizer and GSK, addressing costs and confidentiality.

During Lacalle's meeting with British Prime Minister Boris Johnson, the launch of a sovereign bond linked to sustainability goals was discussed Pharmaceutical giant GlaxoSmithKline (GSK ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

The approval is based on successful trials demonstrating its efficacy and safety, positioning GSK as a leader in addressing type 2 inflammation-related diseases. More about GlaxoSmithKline GSK is ...

Other FP9 and MVA polyprotein constructs including combination vaccines with CS and LSA1 antigens are being developed at the University of Oxford with the European Malaria Vaccine Initiative (EMVI ...

Drugmaker GSK said, a stamp has been released by India ... Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Ltd, said that “re-invention and resilience,” were key to ...

GlaxoSmithKline (GSK) continues to be the subject of takeover speculation, with Roche and Johnson & Johnson (J&J) now rumoured to be interested in bidding for the UK firm. There does not seem to ...